Market Segments & Statistics:

Global Artificial Insemination Market Size: Information by Type (Intrauterine Insemination, Intracervical Insemination), By End-Use (Fertility Clinics, Home), and Region - Forecast till 2030. According to the reports published, the Global Artificial Insemination Market Size is expected to grow at a CAGR of 8.8%, earning a valuation of USD 5.3 Billion by 2030, from its early figures of USD 3.17 Billion in 2021.

 

Market Overview

The Global Market for Artificial Insemination will reach USD 5.3 billion by 2030, expanding at a compound annual growth rate (CAGR) of 8.8% from USD 2.17 billion in 2021.
 

Globally, the number of people who cannot produce children has increased over the past few decades. According to a 2010 WHO poll, approximately 10% of women experience infertility in some capacity. According to the study conducted by the National Institutes of Health, approximately 12% of couples of reproductive age have difficulty conceiving. Intrauterine Insemination (IUI) commanded the lion's share of the market in 2018 and is anticipated to become one of the fastest-growing sectors in the coming years. It is the most prevalent method of starting a family. Typically, it is a non-invasive technique that can be performed with or without medication. This procedure has a better success rate than other forms of insemination because the sperm sample is placed closer to the eggs. Intravaginal insemination is projected to be the second-fastest expanding segment over the forecast period. This procedure can be performed at home or in a reproductive clinic.
 

Market Drivers for the Global Artificial Insemination

Constant increases in the infertility rate, along with rising awareness and social acceptability of assisted reproductive technologies, serve as the market's primary growth driver.

The global rate of infertility is increasing due to the prevalence of disorders such as erectile dysfunction and Polycystic Ovary Syndrome (PCOS). Changes in lifestyle and the desire of a growing number of working women to have children later in life may create complications. Stress, alcohol consumption, a change in lifestyle, and a decrease in the amount and mobility of sperm all contribute to male infertility. The global market for artificial insemination is driven by the steady increase in male and female infertility.
 

For artificial insemination to be successful, you must determine how far a sperm must travel to fertilize an egg. The type of insemination used depends on the woman's inability to conceive. Age is the most crucial factor in determining whether a woman becomes pregnant spontaneously or with assistance. After a woman reaches the age of 30, her fertility typically begins to decline. The biggest number of infertile individuals are in their late 30s and early 40s. Women above the age of 35 are considered to be of "advanced reproductive age" and should be examined and treated promptly.
 

Globally, the number of people who cannot produce children has increased over the previous decade. WHO estimates that approximately 10% of women are directly or indirectly impacted by infertility. In poor nations, one in four couples has difficulty conceiving due to infertility. This affects approximately 12 percent of childbearing-age couples. Male and female infertility variables are extremely complicated, making it difficult to estimate information on infertility.
 

Rising social acceptance and awareness of new technologies for infertility is a key market driver for artificial insemination.

Even though IVF is a more sophisticated form of Assisted Reproductive Technology (ART), artificial insemination is typically the initial step in treating infertility. People once prohibited art because they believed it was immoral, unnatural, or unethical. Community people, family members, and friends judged families whose children were born through ARTs. Government programmes and changes to the law are driving the demand for artificial insemination operations. About fourteen states in the United States offer health insurance plans that include infertility treatment. The Canadian government is taking measures to stop the population decline. For instance, it has paid for multiple IVF cycles and artificial insemination. Also, Canadians who undergo fertility treatments are eligible for tax credits of up to 40%. In certain instances, the NHS in the United Kingdom will cover up to six Intrauterine Insemination (IUI) cycles.
 

Restraints for the Global Artificial Insemination– 

Unfavourable government regulations can hinder the expansion of the market.

In countries with limited resources, access to ARTs such as artificial insemination remains difficult. According to the World Health Organization, 180 million people worldwide have difficulty conceiving. If you are unable to receive a prompt diagnosis or treatment for infertility, or if it takes too long to receive them, it may decrease your chances of becoming pregnant. In undeveloped and emerging countries, there is a significant disparity between the number of individuals who require reproductive health care and the number of people who receive it. How to manage assisted reproduction is governed differently in various nations. In certain nations, such as the United States, scientific and medical committees at the national level have established professional standards. Other nations have enacted regulations governing how ART may be utilised. Artificial insemination is not widely used because of the high cost. Some governments provide a limited number of free IUI and IVF cycles, but the success rate is average. Additionally, in some locations, ART is not covered by health insurance for couples of the same gender. Artificial insemination is viewed as socially taboo in some communities. This means that children born using this approach receive a great deal of ridicule from their classmates. Catechism states that artificial insemination is less morally reprehensible for married couples, but it is nonetheless morally reprehensible because it is an unnatural method of conception.
 

Opportunities in the Global Artificial Insemination Market – 

Standardization and Guidelines for artificial insemination processes generate chaos for clinics and beginners to the field.

Standardizing rules across nations increases the popularity of operations since it keeps patients safer. Also, according to government regulations, the identities of donors are concealed. Therefore, it allows couples the opportunity to employ artificial insemination. In underdeveloped countries, where ten percent of women have difficulty conceiving and establishing a family, it is difficult to locate infertility treatments. Bringing awareness to the issue of infertility will contribute to the expansion of the market. As more people in developing nations learn about infertility treatments and offer cost-effective, high-quality services to patients, the sector is ripe for expansion. Also, government funds to assist with the establishment of clinics could increase the earnings potential of market newcomers. Several clinics are utilising mergers and acquisitions to expand their service offerings. This is a popular fashion choice in Spain, Australia, Sweden, and the United Kingdom. In May 2016, for instance, Vitrolife acquired Octax and MTG to expand their laser technology for infertility treatment.
 

Segmental Analysis of the Global Artificial Insemination Market – 

The global market for artificial insemination is split by product type and application. The by-type segmentation of the aforementioned market is subdivided into Intrauterine Insemination and Intracervical Insemination, with intrauterine insemination accounting for the largest market share.
 

Intrauterine Insemination - Intrauterine insemination is the most dominating and popular type of artificial insemination, with a market value of USD 1,332.5 million in 2021 and a CAGR of 8.9% to reach USD 30,856 million by 2030. The Intrauterine Insemination or IUI is a type of assisted reproductive technology in which sperm are placed directly into the uterus via a catheter. IUI is the most prevalent method of conception. Injecting sperm into the uterus brings them closer to the eggs and increases the likelihood of fertilisation. The IUI is planned around a woman's ovulation cycle in order to enhance the likelihood of conception. Utilizing ultrasound, hormonal analysis is utilised to monitor the progression of the process.
 

Intracervical Insemination– Intracervical insemination is the second leading segmentation by type with a market value of USD 219.7 million in 2021 and is projected to reach USD 439.1 million by 2030 at a CAGR of 8%. Intracervical Insemination (ICI) is injecting sperm into the outer portion of a woman's cervix so that the sperm can migrate into the uterus and fallopian tubes on their own. This insemination technique is less prevalent than IUI and IVI since it does not result in as many pregnancies.
 

By end-use, the said market is further segmented into fertility clinics and homes, with fertility clinics holding the largest market share.

Fertility Clinics - The fertility clinics hold the largest market share in the aforementioned segmentation, with a market value of $1,693.8 million in 2021 and projected growth to $3,529.6 million by 2030 at an annual growth rate of 8.5%. All types of artificial insemination treatments can be performed in fertility clinics. Most Intrauterine Insemination (IUI) and Intratubal Insemination (ITI) treatments are performed in infertility clinics. Before beginning insemination at a clinic, a consultation is required to determine when the lady is likely to ovulate. In addition, doctors can prescribe medications that improve the likelihood of conception.
 

Home  Home end-users accounted for a market value of USD 234.7 million in 2021 and are projected to reach USD 453.7 million by 2030, a CAGR of 7.6%. Both Intracervical Insemination and Intravaginal Insemination can be performed at home. With home insemination kits, sperm can be introduced into the cervix or vaginal region. These treatments should be performed around the time of ovulation for optimal outcomes.
 

Regional Analysis For The Global Artificial Insemination Market – 

The global artificial insemination market is mainly segmented into three regions, namely North America, Europe, and Asia-Pacific, where the Europe is the most dominant region having a major share of the market. 
 

Europe – Europe's market value in 2021 was USD 749.3 million and is projected to reach USD 1600 million by 2030, a CAGR of 8.8%. Europe is reputed to be one of the world's leading providers of healthcare facilities, which explains why it leads this market category in terms of resources and population awareness.
 

Asia-Pacific- Asia-Pacific is the second-largest market segment in the aforementioned market, with a market value of USD 592.5 million in 2021 and a CAGR of 9% to reach USD 1286.8 million. As a result of developments in the healthcare industry occurring in the region, Asia-Pacific will soon become a hub for healthcare facilities. As a result, the market for healthcare facilities is seeing stable expansion in Asia-Pacific.
 

North America– Listed as the third region in the aforementioned segmentation, North America has a market value of USD 451,1 million in 2021 and is projected to reach USD 916,8 million by 2030 at a CAGR of 8.2%.

 

Competitive Analysis For The Global Artificial Insemination Market –

The leading players in the global artificial insemination market are – Vitrolife, Genea Limited, Rinovum Women's Health, Pride Angel, Hi-tech Solutions, Fujifilm Irvine Scientific, Kitazato Corporation, etc. Conceivex Inc., FUJIFILM Irvine Scientific Inc. (Fujifilm Holdings Corporation), Genea Limited, Genus plc, Hamilton Thorne Inc., Hi-Tech Solutions, Kitazato Corporation, Pride Angel, Rinovum Women’s Health LLC, Rocket Medical plc, TenderNeeds Fertility LLC and Vitrolife AB.
 

Recent Developments By Major Competitors –

• In December 2021, Vitrolife purchased Igenomix and incorporated it into this business as a genetic services division.
• Beginning in May 2022, Genea Limited began to incubate new technology innovations to break down the boundaries surrounding the artificial fertility procedure.
• In May 2022, Rinovum Women's Health inked a contract with the world's largest pharmaceutical company, Target, to design safe and effective artificial fertility processes.
• Fujifilm Irvine Scientific acquired Shenandoah Biotechnology in March 2022 in order to provide local cell culture for vaccines and other medicines.